Cytokine and CAM Antagonists Clinical Prior Authorization Updates

Information posted June 07, 2019

The Vendor Drug Program (VDP) will revise the Cytokine and cell-adhesion molecule (CAM) Antagonists clinical prior authorization on June 25, 2019. The updates account for the following changes in the drug class:

- The clinical prior authorization criteria for Olumiant was approved by the Drug Utilization Review Board on January 25, 2019 for Medicaid clients who are 18 years of age and older with diagnosis of rheumatoid arthritis who failed prior tumor necrosis factor (TNF) blocker treatment, and do not have the "drug-drug" or "drug-disease" contraindications documented on the product package insert.
- In March 2019, the Federal Drug Administration (FDA) approved Cimzia for treatment of adults with non-radiographic axial spondyloarthritis with objective signs of inflammation. The criteria will expand indication for treatment of the population.
- The FDA also approved Ilumya in March for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The criteria will allow Medicaid clients who are 18 years of age and older who meet these conditions.

The Cytokine and CAM Antagonists Clinical Criteria guide is available for review.

This prior authorization remains optional for Medicaid managed care. The Pharmacy Clinical Prior Authorization Assistance Chart shows the prior authorization each managed care organization (MCO) uses and how those authorizations relate to the authorizations used for traditional Medicaid claim processing. This chart is updated quarterly. Providers can also refer to the MCO Resources for links to each MCO's list of clinical prior authorizations.

Questions about this change can be sent by email to vdp-formulary@hhsc.state.tx.us.